Showing posts with label China Research And Intelligence Co.. Show all posts
Showing posts with label China Research And Intelligence Co.. Show all posts

Thursday, August 1, 2013

Study Report: Global And China Human Vaccine Industry 2013-2017 Available at MarketResearchReports.biz

Research Report On Global And China Human Vaccine Industry, 2013-2017
 
The research object of the report is human vaccines. According to different types and sources, vaccines can be divided into pathogenic protein vaccine, recombinant protein vaccines, immune protein vaccines and gene vaccines. 

To Read The Complete Report with  TOC :


In China, vaccines are generally divided into Vaccine I and Vaccine II. Vaccine I is offered for free, and it's priced and purchased uniformly by the government, covering the major epidemic diseases of Hepatitis B, epidemic cerebrospinal meningitis, Tetanus, etc. Vaccine II is other vaccines inoculated voluntarily at residents' own expense. It is independently priced and has large profit margins, but there are intense competition in the market. The frequentlyused Vaccine II includes Pneumonia vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine, Rabies Vaccine and so on. In China, Vaccine I market are occupied by stateowned enterprises, while foreignfunded enterprises and private enterprises have certain advantages in Vaccine II market. 

In 2012, the scale of Chinese vaccine market was about CNY 19 billion, while the scale of pharmaceutical industry was about CNY 1.78 trillion in the same period. The sales revenue of Chinese vaccine industry was only about 1% of that of the pharmaceutical industry far below the global average level of 3%, estimated by CRI. There is still much space for growth.

To Buy a Copy Of This Report:-

China has the largest population in the world with 10 million newborns yearly. Meanwhile, the aging of the society is increasingly serious. With the economic development and increasingly frequent population immigrations, it inevitably widens the spreading range and increases the speed of disease spreading. Accordingly, new epidemic diseases (Avian Influenza, Influenza A H1N1 and so on) occur frequently. 



Contact:-
M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email:        sales@marketresearchreports.biz
Blog:          http://marketsbuzz.wordpress.com/  

Most Visited Report: Global And China In-Vitro Diagnostic Reagent Industry 2013-2017 Available at MarketResearchReports.biz


Global And China In-Vitro Diagnostic    Reagent Industry, 2013-2017
 

In Chinese market, there are mainly three categories of invitro diagnostic reagents, biochemical diagnostic reagents, immune diagnostic reagents and molecular diagnostic reagents, accounting for about 65% of invitro diagnostic reagent market in total in 2012. 

To Read The Complete Report with  TOC :


Global invitro diagnostics market is mature and the concentration rate is high. The 8 major enterprises account for over 70% market share. In 2011, the market scale of global invitro diagnostics reached USD 46 billion, among which developed countries accounted for over 80%. Currently, emerging economic entities occupy low proportions, while their growth rates are far ahead of that of mature markets. 

In China, barriers to entry of this industry are not high and the concentration rate is low. The majority of enterprises concentrate in the biochemical reagent field, so the competition is mainly in the biochemical field. Both the supply and demand of immune and molecular products are prosperous. In addition to immune reagents, markets of other diagnostic reagents are mainly occupied by Chinese domestic enterprises. Although China invitro diagnostic reagent industry started late and its scale is limited, it grows rapidly. In 2012, the market scale reached CNY 13.6 billion, among which immune diagnostic reagents, biochemical diagnostic reagents and molecular diagnostic reagents ranked among the top. 

To Buy a Copy Of This Report:-

According to the investigation of CRI, the production line utilization of various invitro diagnostic reagent manufacturers is universally high. Therefore, CRI predicts that the production capacity of the industry will expand in the future. Furthermore, the development strategy of most enterprises is transversely enriching product varieties and vertically developing towards the upstream and downstream. 



Contact:-
M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email:        sales@marketresearchreports.biz
Blog:          http://marketsbuzz.wordpress.com/

Latest Report On Global And China Blood Product Industry 2013-2017 Available At MarketResearchReports.biz


Research Report On Global And China Blood Product Industry, 2013-2017
 
Blood products are made by separating and extracting various proteins in plasma and classified into albumin products, immune globulin products, coagulation factor products and other blood products. China enterprises mainly produce nine kinds of products of the first three categories.

To Read The Complete Report with  TOC :


The concentration rate of global blood products is very high and the 5 enterprises of developed countries occupy 8085% of the market. The global plasma volume in 2012 exceeded 30,000 tons and the market scale reached USD 17.5 billion, increasing by 7.4% YOY. The current global blood product market remains relatively stable, mainly driven by emerging economies. 

There are strict regulations and high barriers to entry in China blood product industry. No new blood product manufacturing enterprises are allowed to be further established and the import of most blood product varieties is limited. By July 2013, there are only about 20 blood product manufacturers with normal production in China, with small annual plasma volumes and a low market concentration rate. 

In 2012, China blood product enterprises realized a total plasma volume of 3,300 tons which decreased compared with that in 2011. The major reason was that the plasmacollecting volume of Guizhou Province accounted for nearly 30% of the total volume in China and the shutdown of many plasma stations in the province led to the drop of plasma volume in 2012. 


To Buy a Copy Of This Report:-

As new plasma stations have been gradually put into operation since 2011, the plasma volume is expected to recover in 2013 and gradually reach 3,520 tons in 2011. The plasma volume will start to grow from 2014. In 2012, the market scale of China blood products was CNY 14 billion, increasing by approximately 25% YOY, mainly owing to the rise of product unit price caused by short supply. As the output volume of China blood products falls far behind domestic demand, there is no fierce competition in the market. Most products are sold at prices higher than that in the international market.
 


Contact:-
M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email:        sales@marketresearchreports.biz
Blog:          http://marketsbuzz.wordpress.com/

Popular Report: China Tire Retreading Industry And Forcast 2017


China Tire Retreading Industry - Overview And Forecast To 2017



In 2012, the output volume of radial tires in China reached over 460 million and the volume of scrap tires exceeded 200 million. The output volume of retreaded tires in 2012 was 18 million, increasing by more than 10% over 2011 and the market scale exceeded CNY 6 billion. However, the market concentration rate of China tire retreading industry is rather low. According to incomplete statistics, although there are about 500 regular tire retreading enterprises and a number of small workshops in China, retreading over 30 million tires annually, less than 20 of them had an annual production of more than 100,000 units in China in 2012. 

To Read The Complete Report with  TOC :


With the yearly increase of automobile reserves in China, the volume of scrap tires generated has kept growing by over 10% annually and scrap tires have become a major source of solid waste pollution. There are many ways in recycling tires and retreading is one of the important ways. Compared with new tires, retreaded tires consume less resource and are sold at lower prices. However, the overall development of China tire retreading industry lags behind that of new tire industry due to many special reasons.


To Buy a Copy Of This Report:-

Firstly, Chinese consumers usually have misconceptions about the tire retreading industry. Retreaded tires are often considered to be unsafe and produced by small workshops. Besides, some Chinese media constantly vilify tire retreading industry as "illegal business" and highly polluting. As a result, many vehicle owners refuse to use retreaded tires. 



Contact:-
M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email:        sales@marketresearchreports.biz
Blog:          http://marketsbuzz.wordpress.com/

Latest Global And China Study Report: Monoclonal Antibody Industry 2013-2017 Available at MarketResearchReports.biz

Research Report On Global And China Monoclonal Antibody Industry, 2013-2017


Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on.

To Read The Complete Report with  TOC :

In terms of the global market, antibody drugs account for over 40% of the entire biotech drug market and the market share still keeps increasing. Antibody drugs have become one of the most important parts of biotech drugs and monoclonal antibody drugs are even star products of antibody drugs. Among the top 10 best selling drugs in 2012, six of them were monoclonal antibody drugs with each annual sales value exceeding USD 5 billion.

In recent years, the market scale of monoclonal antibody drugs increased rapidly. In 2012, the global sales value of monoclonal antibody preparation exceeded USD 50 billion. Among that, Roche (plus Genentech) was the leading monoclonal antibody enterprises, which possessed seven products sold in the market including Avastin, Herceptin, Rituximab, etc. In 2012, its sales value of monoclonal antibody products reached USD 20 billion. Mono antibody drugs will become the main force promoting the development of biological drugs in the next few years.

To Buy a Copy Of This Report:-


In recent years, China bio pharmaceuticals industry develops rapidly, but antibody drugs lag far behind the average international level with sales value being less than 3% of biological drug share. At present, China antibody drug market is still in the initial stage. However, with Shanghai CITIC National Health Pharmaceutical Co., Ltd. and Biotech Pharmaceutical Co., Ltd. releasing humanization products, product types of domestic antibody drugs will enter the upgrading stage. Although domestic full humanization products have not been released, humanization products and full humanization products will become the domestic trend of monoclonal antibody products in the future.
  

Contact:-
M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email:        sales@marketresearchreports.biz 
Blog:          http://marketsbuzz.wordpress.com/